Literature DB >> 7873384

Prognostic value of S-phase cells in AML patients.

M B Vidriales1, A Orfao, M C López-Berges, M González, A López-Macedo, J Ciudad, A López, M A García, J Hernández, D Borrego.   

Abstract

Until now, reports on the cell cycle distribution of AML patients have shown highly variable results which are probably related to the technical heterogeneity of such studies. The aim of the present paper was to analyse in 204 AML patients at diagnosis the proliferative rate (assessed by the number of S-phase cells) of peripheral blood (PB) (126 cases) and bone marrow (BM) (78 cases) cells in order to explore its relationship with disease characteristics. A strong parallelism was observed regarding the relationship between the proliferative rate of the blast cells both in PB and in BM and the disease characteristics. Cases with a high proliferative rate were associated with advanced age, high WBC counts and LDH serum levels, monocytic leukaemias (assessed both by morphological and immunophenotypic criteria) and NK-associated antigens (CD56, CD16). The proliferative activity did not influence the CR rate; in contrast, cases with a high number of S-phase cells had shorter survival. In addition, multivariate analysis showed that age, the expression of CD11b, and the S-phase counts are the only three prognostic factors displaying an independent impact on survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7873384     DOI: 10.1111/j.1365-2141.1995.tb03310.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Authors:  Simona Lapusan; Maria B Vidriales; Xavier Thomas; Stephane de Botton; Anne Vekhoff; Ruoping Tang; Charles Dumontet; Rodica Morariu-Zamfir; John M Lambert; Marie-Laure Ozoux; Philippe Poncelet; Jesus F San Miguel; Ollivier Legrand; Daniel J DeAngelo; Francis J Giles; Jean-Pierre Marie
Journal:  Invest New Drugs       Date:  2011-04-26       Impact factor: 3.850

2.  Chromatin-bound PCNA as S-phase marker in mononuclear blood cells of patients with acute lymphoblastic leukaemia or multiple myeloma.

Authors:  F Zölzer; O Basu; P U Devi; S P Mohanty; C Streffer
Journal:  Cell Prolif       Date:  2010-12       Impact factor: 6.831

Review 3.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

4.  Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway.

Authors:  Yong Luo; Jeffrey W Pollard; Arturo Casadevall
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

5.  Diagnostic and prognostic values of S-phase fraction and aneuploidy in patients with bone marrow aplasia.

Authors:  Payal Tripathi; Anil Kumar Tripathi; Ashutosh Kumar; Rizwan Ahmad; Anil Kumar Balapure; Achchhe Lal Vishwakerma
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

6.  Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.

Authors:  P Kaaijk; G J L Kaspers; E R Van Wering; G J Broekema; A H Loonen; K Hählen; K Schmiegelow; G E Janka-Schaub; G Henze; U Creutzig; A J P Veerman
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.